If you have been reading about ghrelin receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Ipamorelin 是一种合成五肽，序列为 Aib-His-D-2-Nal-D-Phe-Lys-NH2，分子式 C38H49N9O5，游离碱分子量约 711.85 g/mol。它属于生长激素促分泌素（GHS）家族，作用靶点是胃饥饿素受体 GHS-R1a。该化合物由诺和诺德的研究团队在二十世纪九十年代末报道，设计目标是提高对生长激素释放的选择性。C 端酰胺化与 N 端 Aib 残基是两个用于抵抗肽酶降解的结构特征。
在 GHS 家族中，早期肽类如 GHRP-6 与 GHRP-2 会同时促进生长激素、皮质醇与催乳素的释放，并明显增加食欲。Ipamorelin 在动物与早期人体研究中表现出对生长激素释放的相对选择性，对上述其他激素的影响较小。这种差异通常归因于受体结合模式与下游信号偏向的不同，而完整的分子解释仍有待补充。需要区分的是，选择性是研究观察中的相对程度，并非绝对界限。
从用途定位看，ipamorelin 目前主要以研究用肽的身份被讨论，未见主要药品监管机构将其批准为治疗药物。市售材料通常标注仅供研究使用，不得用于人体或诊断程序。文献中它常与生长激素促分泌素、GHS-R1a 激动剂、胃饥饿素拟似物等表述并列出现。既有研究的样本量普遍偏小，因此对其效应强度与一致性的描述应保持谨慎。
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Pentapeptide with C-terminal amide |
| Average mass | Approximately 711.9 Da | Value derived from the formula |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and aqueous acetonitrile | Dissolution aided by acidic diluents |
| Common synonyms | Ipamorelin; NNC 26-0161 | Code name used in early reports |
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
=== Corrosion control === Packaging for metal products can contain volatile corrosion inhibitors, also known as vapour-phase corrosion inhibitors. These compounds evaporate within an enclosed package and form a protective molecular layer on exposed metal surfaces. Volatile corrosion inhibitors may be incorporated into paper, polymer films, foams, oils, emitters, chips, and other packaging materials. Their effectiveness depends on inhibitor concentration, package sealing, storage conditions, metal type, and the volume of the enclosed space. Corrosion-control packaging is used for machinery, automotive parts, tools, electronic components, military equipment, and metal products stored or transported in humid environments.
Graphene was properly isolated and characterized in 2004 by Andre Geim and Konstantin Novoselov at the University of Manchester. They pulled graphene layers from graphite with a common adhesive tape in a process called micro-mechanical cleavage, colloquially referred to as the Scotch tape technique. The graphene flakes were then transferred onto a thin silicon dioxide layer on a silicon plate ("wafer"). The silica electrically isolated the graphene and weakly interacted with it, providing nearly charge-neutral graphene layers. The silicon beneath the SiO2 could be used as a "back gate" electrode to vary the charge density in the graphene over a wide range. This work resulted in the two winning the Nobel Prize in Physics in 2010 for their groundbreaking experiments with graphene. Their publication and the surprisingly easy preparation method that they described, sparked a "graphene gold rush". Research expanded and split off into many different subfields, exploring different exceptional properties of the material—quantum mechanical, electrical, chemical, mechanical, optical, magnetic, etc.
The secret behind a spider web's stickiness lies in the tiny glue droplets dotting its silk threads. Orb-weaver spiders, such as Larinioides cornutus, coat their silk with a special hygroscopic substance that keeps the glue soft and tacky by drawing in water from the air. This built-in humidity control prevents the adhesive from drying out too quickly. The hardening of the viscoelastic protein is indirectly controlled by changes in water content, which in turn affect the concentration of the ionic liquid. As this balance shifts, the glue's viscosity adjusts, helping the web maintain its grip on captured prey. The web is electrically conductive which causes the silk threads to spring out to trap their quarry, as flying insects tend to gain a static charge which attracts the silk. Neurotoxins have been detected in the glue balls of some spider webs. Presumably these toxins help immobilize prey, but their function could also be antimicrobial, or protection from ants or other animals that steal from the webs or might attack the spider. Spider silk has greater tensile strength than the same weight of steel and much greater elasticity. Its microstructure is under investigation for potential applications in industry, including bullet-proof vests and artificial tendons. Researchers have used genetically modified mammals and bacteria to produce the proteins needed to make this material.
Sources: en.wikipedia.org
== Future of the enzyme == Currently, it is seen that bacterial flavin reductase can be used to sensitize carcinomas, or tumors to pro drugs. At first, flavin reductases were used to target the hypoxia of tumors. However, current research is showing an interest in these reductase molecules, specifically, MSuE from Pseudomonas aeruginosa which has been shown to increase the effectiveness of the prodrugs for cancerous tumors. A dual flavin reductase has been shown to participate in the activation of anticancer drugs. There are also molecules that when oxidized can be carcinogenic. In this case, it is helpful to have flavin reductase to reduce these molecules, such as carcinogenic chromate.
unique DNA Also non-repetitive DNA. A class of DNA sequences determined by C0t analysis to be present only once in the analyzed genome, as opposed to repetitive sequences. Most structural genes and their introns are unique.
Recent research has shown that commercially available UVA LEDs (365 nm) are already effective disinfection and sterilization devices. UV-C wavelengths were obtained in laboratories using aluminium nitride (210 nm), boron nitride (215 nm) and diamond (235 nm).
=== Maternal bonding === Of all human bonds, the maternal bond (mother–infant relationship) is one of the strongest. The maternal bond begins to develop during pregnancy; following pregnancy, the production of oxytocin during lactation increases parasympathetic activity, thus reducing anxiety and theoretically fostering bonding. It is generally understood that maternal oxytocin circulation can predispose some mammals to show caregiving behavior in response to young of their species. Breastfeeding has been reported to foster the early post-partum maternal bond, via touch, response, and mutual gazing. Extensive claims for the effect of breastfeeding were made in the 1930s by Margaret Ribble, a champion of "infant rights," but were challenged by others. The claimed effect is not universal, and bottle-feeding mothers are generally appropriately concerned with their babies. It is difficult to determine the extent of causality due to a number of confounding variables, such as the varied reasons families choose different feeding methods. Many believe that early bonding ideally increases response and sensitivity to the child's needs, bolstering the quality of the mother–baby relationship—however, many exceptions can be found of highly successful mother–baby bonds, even though early breastfeeding did not occur, such as with premature infants who may lack the necessary sucking strength to be successfully breastfed. Research following Bowlby's observations (above) created some concern about whether adoptive parents have missed some crucial period for the child's development.
Sources: en.wikipedia.org
It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.
It has not received marketing approval as a medicine in the United States or the European Union. Supplied material is generally described and handled as a research chemical. Regulatory treatment varies by jurisdiction, and some countries restrict growth hormone secretagogues under sports or medicines legislation.
Earlier secretagogues were associated with broader hormonal responses, including measurable changes in cortisol and prolactin. Reports on this peptide describe a narrower profile in which growth hormone release is the most prominent effect. The observation is influential because it shapes how the compound is compared with other members of the same receptor family.
两者都是 GHS-R1a 激动剂，但 ipamorelin 在研究中显示出更高的生长激素释放选择性。早期资料显示它对皮质醇、催乳素与食欲的刺激弱于 GHRP-6。这些差异是相对程度，而非绝对区分。